Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Zenapax (Hoffmann-La Roche Inc): Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Zenapax (Hoffmann-La Roche Inc) - General Information

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Zenapax (Hoffmann-La Roche Inc) is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.

 

Pharmacology of Zenapax (Hoffmann-La Roche Inc)

Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.

 

Zenapax (Hoffmann-La Roche Inc) for patients

 

Zenapax (Hoffmann-La Roche Inc) Interactions

 

Zenapax (Hoffmann-La Roche Inc) Contraindications

ZENAPAX is contraindicated in patients with known hypersensitivity to Daclizumab or to any components of this product.

 

Additional information about Zenapax (Hoffmann-La Roche Inc)

Zenapax (Hoffmann-La Roche Inc) Indication: For prevention of renal transplant rejection Mechanism Of Action: Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Daclizumab Synonyms: Ig gamma-1 chain C region; Anti-IL-2; Humanized antiCD25 Drug Category: Immunomodulatory Agents; Immunosuppressive Agents Drug Type: Biotech; Approved; Investigational Other Brand Names containing Daclizumab: Zenapax (Hoffmann-La Roche Inc); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes. Half Life: 11-38 days Dosage Forms of Zenapax (Hoffmann-La Roche Inc): Liquid Intravenous Chemical IUPAC Name: Humanized anti-CD25 antibody Chemical Formula: C6332H9808N1678O1989S42 Daclizumab on Wikipedia: https://en.wikipedia.org/wiki/Daclizumab Organisms Affected: Humans and other mammals